Cardiologists back expanded lipoprotein(a) testing for at-risk patients
The Australian Atherosclerosis Society has come out in support of the proposed MBS items
Testing for elevated lipoprotein(a) should be considered in all patients with premature cardiovascular disease and familial hypercholesterolaemia, according to the Australian Atherosclerosis Society.
It also called for new MBS items to fund the tests and for atherosclerotic cardiovascular disease (ASCVD) risk calculators to be updated to include lipoprotein(a) — or Lp(a) — as a predictor variable.
